In the present study, in response to a 60 g oral glucose bolus, we observed an increase in mean iAUC of postprandial glucose, insulin and C-peptide of approximately 100%, 50% and 42%, respectively, in the active versus inactive phase of women taking OCPs containing androgenic progestogens, indicating that androgenic OCP formulations may impair glucose tolerance and increase insulin resistance. This evidence concerns the gene INS and Insulin resistance.